Human papillomavirus type 16 E7 protein (HPV16 E7) (HPV16 E7)

Human papillomavirus type 16 E7 (HPV16 E7) is a potent viral oncoprotein and a critical driver of malignant transformation in HPV-infected cells (Source: NIH National Cancer Institute). It primarily functions by binding to and promoting the ubiquitin-mediated degradation of the retinoblastoma protein (pRb), which releases E2F transcription factors and forces the cell into the S-phase of the cell cycle (Source: PubMed PMID: 10482314). This disruption of the G1/S checkpoint, combined with the actions of the E6 oncoprotein, leads to persistent cellular proliferation and the accumulation of genetic mutations (Source: UniProt P03129). Because E7 expression is required for the maintenance of the malignant phenotype and is exclusively found in infected or transformed cells, it is a high-priority target for cancer immunotherapy. Current clinical approaches include therapeutic vaccines, such as VGX-3100 and ISA101, designed to elicit T-cell responses, and adoptive T-cell therapies like KITE-439 that utilize TCR-engineered T-cells to recognize E7 peptides presented by MHC molecules (Source: ClinicalTrials.gov). These therapies aim to exploit the tumor-specific nature of E7 to achieve targeted destruction of malignant cells while sparing healthy tissue.

Other names

HPV16 E7E7 oncoproteinHuman papillomavirus type 16 protein E7Protein E7

Therapeutic vaccines and TCR-engineered T-cells target the E7 protein to induce immune-mediated destruction of HPV-transformed cells. Vaccines stimulate endogenous T-cell responses against E7 epitopes, while TCR-T therapies provide ex vivo expanded T-cells that recognize E7 peptide-HLA complexes on the tumor cell surface (Source: PubMed PMID: 29158379, 32778565).